Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.54M | 37.33M | 32.22M | 28.04M | 33.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.23M | 57.44M | 56.20M | 57.84M | 70.52M |
| Operating Income | -62.23M | -57.44M | -56.20M | -57.84M | -70.52M |
| Income Before Tax | -61.93M | -58.88M | -57.39M | -56.17M | -67.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.93 | -58.88 | -57.39 | -56.17 | -67.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.93M | -58.88M | -57.39M | -56.17M | -67.81M |
| EBIT | -62.23M | -57.44M | -56.20M | -57.84M | -70.52M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.96 | -1.15 | -1.50 | -1.80 | -2.21 |
| Normalized Basic EPS | -0.57 | -0.68 | -0.92 | -1.12 | -1.39 |
| EPS Diluted | -0.96 | -1.15 | -1.50 | -1.80 | -2.21 |
| Normalized Diluted EPS | -0.57 | -0.68 | -0.92 | -1.12 | -1.39 |
| Average Basic Shares Outstanding | 293.26M | 214.08M | 157.89M | 126.97M | 123.95M |
| Average Diluted Shares Outstanding | 293.26M | 214.08M | 157.89M | 126.97M | 123.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |